14
Views
17
CrossRef citations to date
0
Altmetric
CaseReport Article

Halofantrine-associated Ventricular Fibrillation in a Young Woman with no Predisposing QTc Prolongation

, , , , &
Pages 207-208 | Received 30 Sep 1996, Accepted 28 Nov 1996, Published online: 08 Jul 2009

References

  • ter Kuile F O, Dolan G, Nostern F, Edstein M D, Luxemburger C, Phaipun L, Chongsuphajaisiddhi T, Webster H K, White N J. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993; 341: 1044–1049
  • Nosten F, ter Kuile F O, Luxemburger C, Woodrow C, Kyle D E, Chongsuphajaisiddhi T, White N J. Cardiac effect of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054–1056
  • Karbwang J, Bangchang K Na, Bunnag D, Harinasuta T. Cardiac effect of halofantrine [Letter]. Lancet 1993; 342: 501
  • Castot A, Rapoport P, le Coz P. Prolonged QTc interval with halofantrine [Letter]. Lancet 1993; 341: 1541
  • Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J, Le Bras M. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans Roy Soc Trop Med Hyg 1995; 89: 430–433
  • Touze J E, Bernhard J, Keundjiran A, Imbert P, Viguier A, Chaudet H, Doury J C. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Am J Trop Med Hyg 1996; 54: 225–228
  • Matson P A, Luby S P, Redd S C, Rolka H R, Meriweter R A. Cardiac effects of standard-dose halofantrine treatment. Am J Trop Med Hyg 1996; 54: 229–231
  • Monlun E, Leenhardt A, Pillet O, Gaston R, Receveur M C, Bouabdallah K, Longy-Boursier M, Favarel-Garrigues J C, Le Bras M. Arythmies ventriculaires at prise d'halofantrine. Bull Soc Path Ex 1993; 86: 365–368
  • Toivonen L, Viitasalo M, Siikamäki H, Raatikka M, Pohjola-Sintonen S. Provocation of ventricular tachycardia by anti-malarial drug halofantrine in congenital long QTc syndrome. Clin Cardiol 1994; 17: 403–404
  • Bradley D. Letter to the Editor. Br Med J 1994; 308: 721
  • Mberu E K, Muhia D K, Watkins W M. Measurement of halofantrine and its major metabolite desbutylhalofantrine in plasma and blood by high-performance liquid chromatography: a new methodology. J Chromatogr 1992; 581: 156–160
  • Milton K A, Edwards G, Ward S A, Orme ML'E, Brecken-ridge A M. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmac 1989; 28: 71–77
  • Karbwang J, Bangchang K N. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 1994; 27: 104–119
  • Heinzel G, Woloszczak R, Thomann P. Topfit Version 2.0: Pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fisher Verlag, StuttgartGermany 1992

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.